​​​​​​​PEG-BIO Biopharm Co.,Ltd(chongqing).
News Center
Home >> 行业动态 >> 31 monoclonal antibodies to watch for in 2018
31 monoclonal antibodies to watch for in 2018
Source:药事纵横 | Author:pro954f45 | Published time: 2018-01-14 | 2662 Views | Share:
      overview
      Monoclonal Antibody (Mab). Since the first Monoclonal antibody was introduced in 1986, nearly 80 Monoclonal antibodies have been published worldwide. So far, MONOclonal antibody has been developed to the fourth generation. The first generation is momAB, the second generation is ximab, the third generation is Zumab, and the fourth generation is MUMab. The advantage of humanized monoclonal antibody is that it can overcome the reaction of human anti-mouse antibody, avoid the rapid elimination of monoclonal antibody molecules as foreign proteins by the immune system, and improve the biological activity of monoclonal antibody molecules.

（Image from the Internet）

       Despite the small number of products, there are more than 40 active monoclonal antibodies that support a global market of nearly $100 billion, and the growth rate of the drug market for monoclonal antibodies is far higher than that of other drugs in the industry. Excellent curative effect, huge market and high added value have given rise to a large number of companies developing monoclonal antibody products. In recent years, the development speed of the global monoclonal antibody industry has been significantly accelerated. In 2017, the first monoclonal antibodies approved in the US and Europe reached double-digit levels for the first time, and 2018 is expected to see further highs. As of December 1, 2017, nine monoclonal antibodies are under FDA/EMA review, and 12 have received or will receive critical clinical data, and are expected to file for marketing by 2018. In addition, there are nearly 20 monoclonal antibody products at the terminal clinical stage. In the near future, it will be an era of "hundred ships".